Drugs / PTG-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04524221 | Feb 2021 → Apr 2022 | celiac disease | Nielsen Fernandez-Becker | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02895100 | Dec 2016 → Mar 2018 | ulcerative colitis | Protagonist Therapeutics, Inc. | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTG-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02895100 ↗ |
| Action | Inhibit | “PTG-100 potently and selectively blocks α4β7.” PMID 34474038 ↗ Aug 2021 |
| Modality | Peptide | “PTG-100, an Oral α4β7 Antagonist Peptide” PMID 34474038 ↗ Aug 2021 |
| Route | Oral | “an oral peptide, PTG-100, administered as capsules” NCT02895100 ↗ |